Actively Recruiting
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
Led by Pennington Biomedical Research Center · Updated on 2025-07-24
10
Participants Needed
1
Research Sites
340 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypoglycemic complications are a major impediment to the maintenance of healthy glucose levels in persons with diabetes. The investigators recently completed a clinical pilot and feasibility study (GLIMPSE, NCT02690168), which identified a novel biomarker, glial acetate metabolism, that appears to predict the susceptibility to hypoglycemia. By providing an assay to predict hypoglycemic events and therefore diabetic complications, the development of this biomarker could significantly improve the treatment of persons with diabetes. The goal of this study is to determine the efficacy of our biomarker for predicting susceptibility to insulin-induced hypoglycemia. In order to accomplish this goal the investigatiors will pair our 13C magnetic resonance spectroscopy procedure to assess glial acetate metabolism, developed in the GLIMPSE study, with a hyperinsulinemic-hypoglycemic clamp procedure, developed in the HYPOCLAMP study (NCT03839511). The two procedures will be separated by a three day interval. The investigators will then correlate the participants' rates of glial acetate metabolism with their neuroendocrine responses to the hypoglycemic clamp. This proof of concept study will test the hypothesis that glial acetate metabolism is inversely proportional to the neuroendocrine response to hypoglycemia, that is, as glial acetate metabolism increases the neuroendocrine response will decrease.
CONDITIONS
Official Title
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male or female
- Ages 18-40 years
- BMI between 20 kg/m2 and 30 kg/m2 (±0.5 kg/m2 accepted)
- Medically cleared for participation in the study
You will not qualify if you...
- Contraindication to MRI
- Consume more than 10 alcoholic drinks per week
- History of chronic smoking or quit less than 10 years ago
- History of clinically diagnosed diabetes or fasting blood glucose >126 mg/dL
- Average screening blood pressure >140/90 mmHg
- History of cardiovascular disease
- Pregnant, planning pregnancy, or breastfeeding
- Use of medications affecting glucose metabolism (e.g., benzodiazepines, thiazide diuretics, cortisone, prednisone)
- Use of beta-adrenergic antagonists
- Considered inappropriate for participation by the investigative team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808-4124
Actively Recruiting
Research Team
A
Amber Dragg
CONTACT
B
Bethany Gildersleeve
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here